Resource Utilization and Costs Associated with Using Insulin Therapy Within a Newly Diagnosed Type 2 Diabetes Mellitus Population

Bell, Kelly; Parasuraman, Shreekant; Raju, Aditya; Shah, Manan; Graham, John; Denno, Melissa

doi:10.18553/jmcp.2015.21.3.220

Cited by 6 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Para as pessoas que compram medicamentos para o tratamento do diabetes em famílias com renda familiar per capita de até R$ 400,00, cerca de 40% das suas despesas individuais referem-se à compra desses medicamentos destinados ao tratamento do diabetes. [14][15][16][17][18] Um dos componentes importantes dessa estratégia de tratamento é a prática regular de atividade física, importante para o controle direto e indireto do peso e/ ou dos níveis glicêmicos. Vários estudos têm sido desenvolvidos nessa linha, tanto em humanos como em animais.…”

Section: Resultsunclassified

See 1 more Smart Citation

Contribuições do tratamento não-farmacológico para diabetes mellitus tipo II

Carvalho¹,

Silva²,

Coelho³

2015

Rev Epidemiol Control Infect

View full text Add to dashboard Cite

Exceto onde especificado diferentemente, a matéria publicada neste periódico é licenciada sob forma de uma licença Creative Commons -Atribuição 4. Backgound and Objectives: Considering the type 2 diabetes an important public health problem, with high and increasing number of cases in the country and of its consequences, it has become necessary investment in new areas of research to strengthen the use of alternative therapies, relating benefit cost with lower rates of adverse effects. Thus, this study aimed to identify the benefits of physical activity and specific balanced diet in the control of diabetes mellitus type 2. Such strategies are recognized in the literature as non-pharmacological treatment and used as election therapy or as an adjunct to classical pharmacological treatment. Methods: We conducted a cross-sectional pilot study at the Center for Diabetic Care and Hypertension in a Bahian in a city of Bahia in 2014, based on consultation records and questionnaire. The sample consisted of 56 adult individuals of both sexes, aged >40, with diabetes mellitus type 2, registered and accompanied by the institution for disease control. Results: The average age of participants was 62 years, most are female, with low socioeconomic status, and reported no use of tobacco or alcohol. (85,7%), carbohydrates. Most participants had a mean age of 62 years, female, with low socioeconomic status, and reported no use of tobacco or alcohol. Best of glucose levels also predominated in the sample (85.7%), along with a low daily intake of fat and sugar / sweet carbohydrates, physical inactivity, overweight and previous guidance of oral hygiene. Most also said never done gingival treatment and tooth loss report was almost 100%. Conclusion:The results of this study point to a better relationship between glycemia and non-pharmacological therapies such as guided oral hygiene, physical activity and BMI <25. However, it reinforces the need for more studies of this nature with robust methodological arrangements and greater power of analysis. Your results will bring important gains for the control of diabetes, both collective and individual levels.

show abstract

Section: Resultsunclassified

“…Vários estudos têm sido desenvolvidos nessa linha, tanto em humanos como em animais. 15,16 Destaca-se grande percentual de sobrepeso e ou obesidade detectado na amostra, em um total de 32 pessoas nessa condição. Isso foi predominante nas mulheres, cujo percentual foi maior que 60%.…”

Section: Resultsunclassified

Contribuições do tratamento não-farmacológico para diabetes mellitus tipo II

Carvalho¹,

Silva²,

Coelho³

2015

Rev Epidemiol Control Infect

View full text Add to dashboard Cite

show abstract

“…33 However, insulin therapy is believed to increase the incidence of hypoglycemic events, which lead to increased medical costs, especially physician visit costs. 34 Patients whose medical expenses were covered by the Ministry of National Solidarity, Human Rights, and Gender had a 34.8% increase in predicted COI. The Ministry has an assistance program for those who are unable to afford their medical expenses that only covers medical expenses in public health institutions.…”

Section: Discussionmentioning

confidence: 99%

Exploring cost drivers to improve disease management: the case of type 2 diabetes at a tertiary hospital in Burundi, Africa

Hezagirwa

Riewpaiboon

Chanjaruporn

2023

J. Public Health Afr.

View full text Add to dashboard Cite

Background. In Burundi, the International Diabetes Federation estimated the prevalence of diabetes mellitus (DM) as high as 2.4% in adults aged between 20 and 79 years old. The healthcare expenditure for the treatment of diabetic patients is thus considerably high. Objectives. This study explores the economic burden of type 2 DM and its cost drivers at a tertiary hospital in 2018. It included adult type 2 DM patients who received treatment from a tertiary hospital (Hospital Prince Regent Charles) in 2018. Eighty-one patients were included in the study. Methods. Data on illness treatment and complications were collected through patient interviews and by reviewing patients’ medical and financial records. A stepwise multiple linear regression model was used to explore factors affecting the cost of type 2 diabetes mellitus. Results. The average total cost per patient per year was estimated at $2621.06. The fitted cost model had an adjusted R2 of 0.427, meaning it explained up to 43% of the variation in the total cost. The results suggest primary cost drivers such as treatment regimen, duration of the disease, payment method, and number of complications. Conclusion. The findings confirm the profound economic burden of type 2 DM and the need to improve patient care and prevent disease progression. The establishment of a special clinic for patients with diabetes is recommended, as is financial support for underprivileged patients. A specific focus on cost drivers could help establish appropriate disease management programs to control the costs for type 2 diabetes patients.

show abstract

“…The disease burden related to diabetes is thus high and rising in every country, supported by the global rise in the prevalence of obesity and unhealthy lifestyles [2,10]. Indeed, diabetes and its complications are the major causes of death in most countries [7].…”

Section: Introductionmentioning

confidence: 99%

Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study

Esposti

Perrone

Saragoni

et al. 2019

Journal of Diabetes Research

View full text Add to dashboard Cite

Background. This study is aimed at estimating the proportion of type 2 diabetes mellitus (T2DM) patients treated with basal insulin (insulin glargine U100) and at evaluating daily insulin dose, treatment pattern, and adherence to treatment of these patients. Methods. Data from administrative and laboratory databases of 3 Italian Local Health Units were retrospectively collected and analyzed. All patients with a diagnosis of T2DM between 01/01/2012 and 31/12/2012 were considered, and those with at least a prescription of insulin glargine between 01/01/2013 and 31/12/2014 were included and followed up for one year. For each patient, we evaluated HbA1c levels both at baseline and during the follow-up period and the daily average dose of insulin. Medication adherence was defined by using medication possession ratio (MPR) and reported as proportion of patients with MPR≥80%. Results. 7,422 T2DM patients were available for the study. According to the antidiabetic medication prescribed, patients were categorized into four groups: insulin glargine only, insulin glargine plus oral glucose-lowering drugs, insulin glargine plus rapid-acting insulin, and insulin glargine plus DPP-4 inhibitors. Median daily dose of insulin among insulin glargine only patients was higher than in other groups (35 IU vs. 20 IU, p<0.05), and a higher percentage of them achieved a target HbA1c value of less than 7.0% (53.8% vs. 30%, p<0.001). Adherence to insulin treatment was lowest (41%) in the insulin glargine only group compared to other groups (ranging from 58.4% to 64.4%), p<0.001. Conclusions. A large proportion of T2DM patients treated with insulin fail in achieving the glycemic target of HbA1c level<7%, irrespective of treatment regimen; however, basal insulin only is associated with lower therapeutic unsuccess. Adherence to antidiabetes medications is also suboptimal in these patients and should be addressed to improve long-term outcomes of reducing and preventing microvascular and macrovascular complications.

show abstract

Resource Utilization and Costs Associated with Using Insulin Therapy Within a Newly Diagnosed Type 2 Diabetes Mellitus Population

Abstract: Use of insulin therapy is associated with increased hypoglycemic events, increased pharmacy and medical costs, and greater utilization of T2DM-specific health care services.

Cited by 6 publications

References 28 publications

Contribuições do tratamento não-farmacológico para diabetes mellitus tipo II

Contribuições do tratamento não-farmacológico para diabetes mellitus tipo II

Exploring cost drivers to improve disease management: the case of type 2 diabetes at a tertiary hospital in Burundi, Africa

Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study

Contact Info

Product

Resources

About